07 September, 2017
NASDAQ:SGYP) shares were trading higher by 1.01 percent ($0.03) at $3.01 a piece in Friday's session.
Maximum and minimum EPS estimate for the current quarter is projected at $-0.23 and $-0.31, respectively, according to 6 analysts. If the share price is now hovering near the 52 week low and the value is achieved in the current past then it can suggest that the price of the shares is likely to go up. Market capitalization is the total value of any firm in the stock market. Cantor Fitzgerald restated an overweight rating and set a $11.00 target price on shares of Synergy Pharmaceuticals in a report on Friday, June 9th. Investors who are keeping close eye on the stock of Synergy Pharmaceuticals Inc. A 5 analysts rate it as either a buy or a strong buy, while1 believe that investors should either steer clear of SGYP or, if they already own its stock, sell it. Analyst rating score as published on FINVIZ are rated on a 1 to 5 scale.
Synergy Pharmaceuticals Inc (SGYP) now has a 14-day Commodity Channel Index (CCI) of -17.69. Meanwhile, due to an ongoing pressure which caused a decline of nearly -2.27% in the past five days, the stock price is now down -50.57% so far on the year - still in weak territory. The company's market cap is $677.11 million. The stock has a 50 day moving average price of $3.53 and a 200-day moving average price of $4.28.
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has a beta of 1.44, compared to a beta of 1 for the market, which implies that the stock's price movements are more extreme than the market as a whole. At recent closing price of $22.35, MTCH has a chance to give up $-22.35 or -100% in 52 weeks, based on mean target price ($0) placed by analysts.The analyst consensus opinion of 0 looks like a buy. 113.25 million shares or 15.05% more from 98.44 million shares in 2016Q3 were reported. The Company kept a record of 224.03 million floated shares and 224.19 million shares outstanding. If you are reading this story on another site, it was stolen and reposted in violation of US & worldwide copyright and trademark law. If you are viewing this story on another publication, it was stolen and reposted in violation of United States & global copyright and trademark legislation.
Return on equity reveals how much profit a company earned in comparison to the total amount of shareholder equity found on the balance sheet. Angled up and price is moving up (or was recently) overall, angled down and price is moving down overall, moving sideways and the price is likely in a range. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Whirlpool Corporation (WHR) stock moved with shift of 2.35% in the past week.
Want to see what other hedge funds are holding SGYP? This continues to be an interesting story, and we look forward to updating it again soon on Synergy Pharmaceuticals Inc. A low price-to-sales ratio, typically less than 1.0, is considered a good value. This company right now is valued at $5.71B.
Direxion Daily Small Cap Bear 3X Shares's Williams Percent Range or 14 day Williams %R now sits at -82.21. About 14.13 million shares traded or 236.43% up from the average. TimesSquare Capital Management LLC increased its position in shares of Synergy Pharmaceuticals by 2.7% during the second quarter.
This company shares (SGYP) so far managed to recover 1.75% since collapsing to its 52-week low. Finally, Kingdon Capital Management L.L.C. increased its position in shares of Synergy Pharmaceuticals by 42.7% during the first quarter. The Irving Magee Investment Management holds 203,653 shares with $11.07M value, up from 179,596 last quarter. Cubist Systematic Strategies Limited Liability Company holds 0.01% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) or 16,400 shares. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
